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Abstract
Background & Aims—All-oral regimens combining different classes of direct-acting antivirals
(DAA) are highly effective for treatment of patients with chronic hepatitis C. NS5A inhibitors will
likely form a component of future interferon-sparing treatment regimens. However, despite their
potential, the detailed mechanism of action of NS5A inhibitors is unclear. To study their
mechanisms, we compared their kinetics of antiviral suppression with those of other classes of
DAA, using the hepatitis C virus (HCV) genotype 1a cell culture-infectious virus H77S.3.
Methods—We performed detailed kinetic analyses of specific steps in the HCV life cycle using
cell cultures incubated with protease inhibitors, polymerase inhibitors, or NS5A inhibitors. Assays
were designed to measure active viral RNA synthesis and steady-state RNA abundance,
polyprotein synthesis, virion assembly, and infectious virus production.
Results—Despite their high potency, NS5A inhibitors were slow to inhibit viral RNA synthesis
compared to protease or polymerase inhibitors. By 24 hrs after addition of an NS5A inhibitor,
polyprotein synthesis was reduced less than 50%, even at micromolar concentrations. In contrast,
inhibition of virus release by NS5A inhibitors was potent and rapid, with onset of inhibition as
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early as 2 hrs. Cells incubated with NS5A inhibitors were rapidly depleted of intracellular
infectious virus and RNA-containing HCV particles, indicating a block in virus assembly.
Conclusions—DAAs that target NS5A rapidly inhibit intracellular assembly of gentoype 1a
virions. They also inhibit formation of functional replicase complexes, but have no activity against
pre-formed replicase, thereby resulting in slow shut-off of viral RNA synthesis.
Keywords
antiviral agent; replication; therapy; RNA-dependent RNA polymerase
BACKGROUND
The treatment of chronic hepatitis C is being revolutionized by the availability of direct
acting antivirals (DAAs) that target viral proteins essential for virus replication and that
offer the potential for all oral therapies and cure rates approaching 100%1. The first of these
DAAs, boceprevir (BOC) and telaprevir, were approved for treatment of HCV in 20112.
These linear ketoamides inhibit the major viral protease, NS3/4A, and their addition to
interferon-based therapy increased sustained virologic response rates to 60–80% in
treatment-naïve patients. More recently, a third NS3/4A protease inhibitor, the macrocyclic
compound simeprevir, and a potent nucleotide inhibitor of the viral NS5B RNA-dependent
RNA polymerase, sofosbuvir, have achieved regulatory approval.
DAAs that target NS3/4A (protease) and NS5B (RNA-dependent RNA polymerase) inhibit
the enzymatic activity of these proteins. Detailed knowledge of the structure of these
enzymes and their mechanisms of action greatly facilitated the development of these
compounds. In contrast, small molecule inhibitors that target the viral NS5A protein were
identified by screening libraries for compounds that block amplification of HCV RNA
replicons in cell-based assays3–5. Sequencing of replicons selected for resistance to these
compounds identified NS5A as their target, and more recent data confirm that they directly
bind this viral nonstructural protein4–6. However, the mechanism of action of these NS5A
inhibitors remains unclear. NS5A has no known enzymatic activity, and no cellular
orthologs or viral homologs other than NS5A proteins of other hepaciviruses. Furthermore,
NS5A is known to function in multiple aspects of the HCV life cycle as well as to modulate
aspects of host cell signaling pathways that may favor virus replication7–10.
Although none have yet achieved regulatory approval, multiple NS5A inhibitors are
currently in clinical development. These include, among others, daclatasvir (DCV,
previously BMS-790052), ledipasvir (LDV, previously GS-5885), and MK-87423, 11, 12. As
a class, these inhibitors show substantial promise as anti-HCV therapeutics. With 50%
effective concentrations (EC50) in replicon assays in the low picomolar range, they are the
most potent class of DAA to target HCV. Although NS5A inhibitors appear to have a low
barrier to resistance, they are likely to be a key component of successful interferon-sparing
DAA combinations13, 14.
To better understand the mechanism of action of NS5A inhibitors, we compared the
activities of different classes of DAAs in multiple assays of antiviral activity that
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specifically examine different steps in the viral life cycle, including polyprotein synthesis,
RNA synthesis, and the intracellular assembly and release of infectious genotype 1a virus.
Our results complement recent efforts to develop multi-scale mathematical models of the
clinical response to DAAs15, point to the need for greater attention to the full viral life cycle
in evaluating both antiviral activity and antiviral resistance, and provide fresh insight into
how these emerging therapeutics impact growth of the virus.
MATERIALS AND METHODS
Cell lines and plasmids
Details of cells used in these studies are provided in Supplementary Materials and Methods.
pH77S.3 is an infectious molecular clone of a cell-culture adapted genotype 1a HCV16.
pH77S.3/GLuc2A is a derivative of it that expresses Gaussia princeps luciferase (GLuc)
from sequence inserted between p7 and NS216. L31V, Y93H, and Q30R resistance variants
were constructed by site-directed mutagenesis or custom DNA synthesis. Final plasmid
constructs were verified by sequence analysis.
Virus infections and antiviral assays
HCV RNA was transcribed from XbaI-linearized plasmid DNA using the T7 Megascript kit
(Ambion) from pH77S.3, purified using the RNeasy Mini kit (Qiagen), and electroporated
into Huh-7 cells as described previously17. Cells were cultured for 7 days to allow for HCV
replication levels to reach a stable maximum prior to seeding to different plate formats for
specific antiviral assays. Stock solutions of LDV, DCV, MK-8742, BOC, VPV, HCV-796,
MK-0608 and compound 23 were prepared in DMSO. Additional details can be found in
Supplementary Materials and Methods.
Statistical methods
For determination of 50% (EC50) and 90% (EC90) effective concentrations of DAAs, data
were fit to a four-parameter dose response curve with variable slope using Prism 5.0c for
Mac OS X software (GraphPad Software, Inc.). Results are reported as the estimated
concentration ± 95% confidence interval.
RESULTS
Kinetics of antiviral suppression by different classes of DAAs
We compared the kinetics of antiviral suppression by the NS5A inhibitors, ledipasvir
LDV,18, daclatasvir DCV,3, and MK-8742 with representative inhibitors of other DAA
classes. For inhibitors of the NS3/4A protease, we studied BOC19, a linear ketoamide, and
vaniprevir VPV,20, a macrocyclic protease inhibitor. We also studied MK-060821 a
nucleoside analog inhibitor of the NS5B polymerase, and HCV-79622, a non-nucleoside
NS5B inhibitor. Antiviral activity was assessed by monitoring GLuc secreted from cells that
were stably infected with a cell culture-adapted virus, H77S.3/GLuc2A, that expresses GLuc
as a fusion with its polyprotein (see Methods)16. EC50 and EC90 concentrations of each drug
were estimated at 24, 48, and 72 hrs after the start of treatment based on the quantity of
GLuc secreted over the preceding 24 hrs (Table S1). GLuc secretion is real-time measure of
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viral polyprotein synthesis, and correlates well with intracellular RNA abundance16. For all
classes of DAAs tested, maximum antiviral activity (lowest EC50 and EC90) was not
observed until 48–72 hrs after addition of the compound (Fig. 1). There were substantial
differences in the response kinetics between inhibitor classes, however. While the slopes of
the response curves for both NS3/4A protease (Fig. 1A) and NS5B polymerase (Fig. 1B)
inhibitors were relatively shallow at 24 hrs compared to 48 hrs or 72 hrs, each of these
compounds achieved nearly complete suppression of GLuc secretion at very high
concentrations by 24 hrs (maximum inhibition, Emax = 80–100% at 24 hr, Table S1). In
contrast, the Emax of the NS5A inhibitors, LDV, DCV, and MK-8742 (Fig. 1C), reached a
plateau of 23–26% at low concentrations, and was not increased with higher concentrations
of these DAAs at 24 hrs. This effect remained evident at 48 hrs, when the NS5A inhibitor
Emax ranged from 85–91%, while that of the other compounds was 97–100% (Fig. 1, Table
S1). Thus, despite their high potency (EC50 2–85 pM) at 72 hr, the NS5A inhibitors have
only a limited ability to reduce GLuc secretion (polyprotein synthesis) at 24 hr, even at
concentrations as high as 50 µM. This precluded estimation of the EC50 at 24 hrs for all
three compounds.
Next, we probed the kinetics of antiviral suppression using quantitative real-time qRT-PCR
to assess residual intracellular HCV RNA abundance at various times after the start of
treatment (Fig. 2A, Table S2). These experiments used cells infected with H77S.3 virus with
no GLuc insertion. Results agreed closely with the GLuc assays for BOC, MK-0608 and
LDV activities (compare Figs. 2A with Figs. 1A–C). Notably, LDV demonstrated less
capacity to reduce viral RNA abundance at 12 and 24 hrs compared with BOC or MK-0608,
even at very high concentrations (Fig. 2A, compare center with left and right panels).
Similar results were obtained with the NS5A inhibitor, DCV (Fig. S1A in Supplementary
Material).
We next employed an assay for infectious focus-forming units (FFU) of virus to determine
the quantity of infectious virus released from cells into supernatant fluids at 12–24 hr
intervals following addition of the compound (Fig. 2B). These results were dramatically
different, as both LDV and BOC rapidly inhibited infectious virus release with little if any
difference in the EC50 at 12 vs. 72 hrs of treatment (Fig. 2B, center and left panels, Table
S3). At 12 hrs, BOC was much more potent in the FFU assay (EC50 = 237 nM, Table S3)
compared to the RT-PCR assay (EC50 = 1,930 nM, Table S2). For LDV, however, at 12 hrs
the disparity in the kinetics of suppression of infectious virus release (EC50 = 0.012 nM,
Table S3) versus viral RNA abundance (EC50 = 2,500 nM, Table S2) was much greater.
MK-8742 (Fig. 2C, left) and DCV (Fig. S1B) also rapidly inhibited infectious virus release,
indicating that this is a general property of this class of NS5A inhibitors. The inhibition of
virus release was potent and immediate: 60–90% inhibition within 2–3 hrs of the addition of
MK-8742 or LDV (Fig. 2C right) to the culture medium. Inhibition of infectious virus
release was considerably slower with the non-nucleoside NS5B inhibitor, HCV-796 (Fig.
2C, right). Importantly, we confirmed that this was not due to carry-over of the DAA in viral
titrations (Fig. S2).
Thus NS5A inhibitors, and to a lesser extent BOC and possibly other NS3/4A inhibitors,
have dual effects on the viral life cycle: rapidly suppressing virus release and more slowly
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reducing RNA abundance. However, each class of DAA tested strongly inhibited both RNA
synthesis and virus release by 72 hrs of treatment.
NS5A inhibitors cause an immediate but only partial block in viral RNA synthesis
The data shown in Fig. 2 suggest a delay in inhibition of viral RNA synthesis by BOC and
LDV. To directly assess this, we measured incorporation of 5-ethynyl uridine into newly
synthesized viral RNA during the first 12 hrs of treatment with these compounds (see
Supplementary Methods). These results revealed a striking difference in the effects of these
two compounds on HCV RNA synthesis (Fig. 3A). High concentrations of BOC effectively
ablated new viral RNA synthesis with an Emax approaching 98% (Fig. 3A, left). The BOC
EC50 in this assay was 4670 nM (95% C.I. 3261–6690 nM), approximating the EC50
determined in the RT-PCR assay at 12 hrs (2500 nM) but well above the RT-PCR EC50 at
72 hrs (261 nM) (Fig. 2A, left panel; Table S2). In contrast, very high concentrations of
LDV (>1000 nM) achieved an Emax of only 52% (Fig. 3A, right). However, this degree of
inhibition was reached at very low concentrations. The 50% maximal inhibitory
concentration for this partial suppression of RNA synthesis was 0.059 nM (95% C.I. 0.42–
0.82 nM), which is comparable to the RT-PCR EC50 at 72 hrs (0.027 nM) (Fig. 2A, center
panel; Table S2). Thus, while the NS3/4A inhibitor, BOC, causes an early and complete
suppression of RNA synthesis at very high concentrations, low concentrations of the NS5A
inhibitor, LDV, potently but only partially inhibit RNA synthesis. These data are consistent
with the differences observed in the Emax of these compounds at 24 hrs in the GLuc assays
(Fig. 1), and suggest that NS5A inhibitors may block assembly or otherwise inhibit newly
forming viral replicase complexes, but have no effect upon those already assembled (see
Discussion). Similar studies with MK-8742 suggested that there was little change in the rate
of synthesis of a genotype 1b subgenomic HCV RNA replicon19 until 8 hrs after addition of
the compound (Fig. 3B).
NS5A inhibitors disrupt HCV assembly
The nearly complete inhibition of viral release by NS5A inhibitors prior to shut-down of
viral RNA synthesis and major reductions in viral RNA abundance (Fig. 2A and B, center
panels) could reflect a blockade of cellular egress, or an upstream inhibition of viral
assembly. To distinguish between these possibilities, we measured the impact of LDV on
accumulation of infectious intracellular virus. H77S.3-infected cells were treated with a
range of concentrations of LDV for 24 hrs prior to harvest. Extracellular virus released into
cell culture medium and intracellular infectious virus were quantified by FFU assay (see
Supplementary Methods). These experiments revealed equivalent reductions in intracellular
and extracellular virus titers, with EC50 values ~0.012 nM (Fig. 4A). Thus, LDV disrupts a
step in viral assembly that precedes the release of virus. We confirmed this by analyzing the
sedimentation profile of viral RNA present in lysates of cells treated with LDV at 3× the
EC90 for 6 or 12 hrs (Fig. 4B). Infectious viral particles sedimented as a discrete peak (Fig.
4B, grey bars) in fractions 8–10 of rate-zonal gradients loaded with lysate from untreated
cells, and this was associated with a co-sedimenting peak of viral RNA. After 6 hrs LDV
treatment, this peak was sharply reduced and most HCV RNA had shifted to a more slowly
sedimenting species present in fractions 3–5 (Fig. 4B, red lines). By 12 hrs, the amount of
viral RNA in this slowly sedimenting peak was sharply reduced.
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Collectively, these data indicate that LDV has an immediate (<3 hrs), potent effect on the
intracellular assembly of new virus particles that precedes reductions in viral RNA
abundance. Previous studies demonstrated that NS5A inhibitors induce a redistribution of
NS5A expressed by subgenomic HCV replicons from an ER-like pattern to lipid droplets23,
suggesting a possible explanation for their effect on viral RNA synthesis. We observed the
accretion of NS5A into large aggregates in H77S.3 virus-infected cells treated with LDV
(Fig. S3). However, these changes were not evident until 12 hrs treatment with LDV, and
thus did not correlate temporally with the inhibition of intracellular virus assembly. We did
not observe a redistribution of NS5A to lipid droplets at either early or late time points (Fig.
S3).
Mutations in NS5A confer resistance against disruption of assembly by LDV
Mutations identified in HCV replicons24, and in genotype 1a viruses from patients treated
with NS5A inhibitors25, confer resistance to the effects of these inhibitors on RNA
replication. However, the impact of these resistance-associated variants (RAVs) on virus
production and its ability to be disrupted by NS5A inhibitors are unknown. We thus studied
three commonly reported RAVs: Q30R, L31V and Y93H, each constructed within the
background of H77S.3 virus. Of these, Y93H was the least fit with replication levels
(assessed by GLuc expression) and infectious virus yields reduced by 10- and 100-fold,
respectively, compared to parental virus (Fig. 5A). In contrast, Q30R and L31V were able to
replicate RNA and produce virus at levels within 2-fold that of the parental H77S.3 virus.
The high fitness of Q30R and L31V variants allowed kinetic assessment of the impact of
LDV on replication and virus production. L31V conferred resistance to the immediate
inhibition of virus release by LDV, as well as the inhibition of RNA replication reflected in
the GLuc assay (Fig. 5B). Resistance (fold-increase in EC50), however, was greater for
infectious virus release (Fig. 5B). Importantly, differences in the kinetics of these responses
were unchanged from those observed with H77S.3 virus (Figs. 1C and 2B). Similar results
were obtained with Q30R (Fig. S4). Collectively, these data suggest that interactions of
LDV with amino acid residues 30 and 31 impact its capacity to inhibit both virus assembly
and RNA replication.
A selective PI4KIIIα quinazolinone inhibitor does not disrupt virus assembly
Both hypo- and hyper-phosphorylated forms of NS5A have been observed in many cell
culture systems, and the phosphorylation of specific NS5A residues has been proposed to
independently regulate virus assembly26, 27 or viral RNA replication8. Some results with
genotype 2a JFH1 virus and the genotype 1b Con1 strain suggest that NS5A inhibitors act
by blocking hyper- but not basal phosphorylation of NS5A28, a process that is negatively
regulated by phosphatidylinositol-4 kinase III-α (PI4K-IIIα)29. We found no evidence that
inhibitors alter the phosphorylation status of NS5A in H77S.3-infected cells. However,
unlike NS5A expressed by JFH1 or Con1 that resolves as two bands in immunoblots, only a
single NS5A band is detectable in lysates of H77S.3-infected cells27. Thus, this difference
may be technical in nature, and not indicative of a difference in mechanism of action.
To gain insight into the role played by PI4KIIIα in the antiviral actions of NS5A inhibitors,
we studied a recently described quinazolinone, i.e., ‘compound 23’ [5-(2-amino-4-oxo-3-(2-
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(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-
methoxypyridine-3-sulfonamide], a selective inhibitor of PI4KIIIα with substantial antiviral
activity against HCV30. In the GLuc assay for polyprotein expression, compound 23 evoked
a bi-phasic response. GLuc secretion was significantly enhanced at concentrations between
2.5–25 nM but strongly inhibited above 50 nM (Fig. 6A, left panel). Both positive and
negative effects on GLuc secretion were relatively slow in onset. The inhibitory Emax was
only 44% at 24 hrs, but nearly 100% by 48 hrs. The slow onset of GLuc inhibition was thus
similar to what was observed with LDV and other NS5A inhibitors (Fig. 1C). The EC50 was
82.3 nM (95% C.I. 39.8–170) at 72 hr.
Compound 23 inhibited infectious virus release with an EC50 of 39.2 nM (95% C.I. 36.4–
42.2) by 72 hr, but this effect was also very slow in onset with less than 50% inhibition by
24 hrs at 5000 nM, the highest concentration tested (Fig. 6A, right panel). This contrasts
sharply with the rapid inhibition of infectious virus release with low concentrations of NS5A
inhibitors such as LDV and MK-8742 (Figs. 2B–C and 4). Thus, the inhibition of virus
release by compound 23 is likely related to shutdown of viral RNA synthesis. Taken
collectively, these data indicate that PI4KIIIα activity is not essential for assembly and
release of HCV and that the ability of NS5A inhibitors such as DCV, LDV, and MK-8742 to
disrupt virion assembly is independent of any effect on the NS5A/PI4KIIIα complex.
We also measured 5-EU incorporation into viral RNA between 2–12 hrs after addition of
compound 23 to cell cultures. As with the GLuc assay, low concentrations of the PI4KIIIα
inhibitor caused a modest stimulation of viral RNA synthesis, while concentrations above
100 nM resulted in inhibition (Fig. 6B). The maximal inhibition (Emax) of 5-EU
incorporation was only 41%, however. This was reached at 250 nM, with no greater
inhibition at concentrations up to 5000 nM. Thus, in contrast to the striking difference
between PI4KIIIα and NS5A inhibitors in the FFU assay (Fig. 2B, center vs. Fig. 6A, right),
these different classes of inhibitors act similarly in their suppression of viral RNA synthesis.
As discussed above, these results suggest that compound 23 inhibits new replicase complex
formation but lacks activity against previously formed complexes. This suggests in turn that
PI4KIIIα activity is required for formation of new replicase complexes, but not for ongoing
RNA synthesis by mature complexes.
DISCUSSION
While previous modeling of the therapeutic response to DCV suggested a dual mode of
action involving both inhibition of viral release and suppression of viral RNA synthesis15,
the data presented here provide direct evidence for an immediate (< 3 hrs), effect of NS5A
inhibitors on the intracellular assembly of HCV (Figs. 2 and 4). In the absence of inhibitors,
NS5A is distributed between membrane-bound viral replicase complexes derived from
endoplasmic reticulum where it functions in RNA replication, and lipid droplets to which it
is recruited by core protein and functions in viral assembly26, 31, 32. NS5A inhibitors have
been shown to induce a redistribution of NS5A within the cell23. We found LDV resulted in
the accretion of NS5A into large, cytoplasmic aggregates (Fig. S3). However, this effect was
not evident at early time points when viral assembly was blocked, and correlated more
closely with inhibition of viral RNA synthesis (Fig. S3). LDV and other NS5A inhibitors are
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characterized by highly symmetrical structures, suggesting that they bind NS5A in a dimeric
state6. Although we did not find that LDV enhanced co-localization of NS5A with lipid
droplets as reported for NS5A inhibitors by others23, it seems likely that the inhibitors bind
NS5A in proximity to the lipid droplet given their effect on virus assembly31. Binding of the
inhibitor to NS5A could preclude its participation in protein-protein or protein-RNA
interactions required for virus assembly. The rapidity with which NS5A inhibitors inhibit
release of infectious virus (Fig. 2C) suggests that assembly and release is a very dynamic
process, with newly assembled virus being rapidly exported from the cell.
In addition to the immediate effect on virus assembly, NS5A inhibitors potently induced an
early (<12 hrs) but only partial block in viral RNA synthesis (Fig. 3A, right, and 3B). This
occurred at low concentrations of LDV, only several fold above the EC50 in FFU assays.
Unlike BOC, higher concentrations of LDV did not increase the magnitude of this early
inhibition of RNA synthesis. These data best fit a model, previously proposed based on
subcellular localization and biochemical fractionation analyses of NS5A33, in which NS5A
inhibitors block the assembly of new replicase complexes but are unable to inhibit RNA
synthesis in those that are already formed. Such a model is consistent with the low initial but
increasing Emax observed over time in GLuc assays with NS5A inhibitors (Fig. 1C, Table
S1). Consistent with this hypothesis, live cell imaging has shown that HCV replicase
complexes persist for many hours in cultured cells, with new complexes replacing older
ones at a relatively slow pace34. One possibility is that NS5A inhibitors block new replicase
assembly by disrupting the interaction of NS5A with PI4KIIIα, a key host factor facilitating
membrane recruitment or remodeling required for replicase assembly35, 36. Compound 23, a
relatively specific PI4KIIIα inhibitor, similarly inhibits viral RNA synthesis. NS5A
inhibitors could fail to block RNA synthesis in previously formed replicase complexes
because the dimeric binding site no longer exists or is otherwise not accessible within the
active complex, or possibly because NS5A is no longer required for RNA synthesis once the
complex has assembled.
In contrast, BOC is capable of early, near complete inhibition of RNA synthesis at very high
concentrations (Fig. 3A, left), suggesting it is able to penetrate and disrupt the activity of
preformed replicase complexes. This suggests in turn the surprising conclusion that NS3 has
a continuing function in RNA synthesis within fully assembled replicase complexes,
separate and distinct from its role in polyprotein processing that must precede assembly of
the complex.
Surprisingly, our data also suggest that the NS3/4A inhibitor, BOC, exerts an early blockade
effect on infectious virus release (Fig. 2B). While surprising, NS3 is known to be recruited
to lipid droplets together with NS5A and to function directly in viral assembly10, 37. Some
RAVs associated with resistance to NS3/4A inhibitors also impair viral fitness by negatively
impacting steps involved in the release of infectious virus16. Further experiments will be
required to confirm whether NS3/4A inhibitors act as a class to block assembly or release of
virus and to define how this occurs.
These studies provide novel insight into how NS5A inhibitors impact specific steps in the
life cycle of HCV. Since all of the viral functions required for replication are imparted by
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only ten mature HCV proteins, these proteins are by necessity multi-functional. A more
complete understanding of how DAAs impact these multiple functions should help to
interpret the complex relationships between PK/PD, drug concentrations, and clinical
responses. Our findings also point to the need for greater attention to be paid to the full viral
life cycle in evaluating resistance to DAAs, as most studies of antiviral resistance have
focused only on how resistance mutations influence the replication of subgenomic replicons.
These replicons are incapable of assembly and release as infectious virus, processes that
appear to play central roles in the antiviral response to NS5A inhibitors and some if not all
NS3/4A protease inhibitors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Kinetic analysis of the suppression of H77S.3/GLuc2A virus replication by different classes
of DAAs: (A) NS3/4A protease inhibitors, boceprevir (BOC, linear ketoamide) and
vaniprevir (VPV, macrocyclic); (B) NS5B inhibitors, MK-0608 (nucleoside) and HCV-796
(non-nucleoside); and (C) NS5A inhibitors, daclatasvir (DCV), ledipasvir (LDV), and
MK-8742. FT3-7 cells were electroporated with H77S.3/GLuc2A RNA and passaged for
one week before treatment with a range of DAA concentrations. Supernatant fluids were
harvested from cultures daily and replaced with fresh medium containing DAAs. Results
shown represent mean ± s.e.m. percent reduction in GLuc activity in supernatant fluids
harvested at 24, 48 and 72 hrs after initiation of treatment, where 0% is GLuc activity in the
absence of DAA and 100% is a reduction to background levels (cells transfected with
replication-incompetent H77S-AAG/GLuc2A RNA). Data were fit to a four-parameter dose
response curve.
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Figure 2.
Kinetics of antiviral suppression by representatives of 3 different classes of DAAs: NS3/4A
inhibitors (BOC), NS5A inhibitors (LDV), and NS5B inhibitors (MK-0608). (A) Antiviral
suppression assessed by qRT-PCR measurements of residual RNA abundance at 12, 24, 48
and 72 hrs following initiation of treatment. (B) Antiviral effect of DAAs assessed by
reductions in infectious virus released into supernatant fluids between 0–12, 12–24, 24–48,
and 48–72 hrs after treatment initiation. Infectious virus release was quantified by FFU
assay. Data shown represent mean ± s.e.m. of 2–3 independent results, and were fit to a
dose-response curve as in Fig. 1. (C) Kinetics of inhibition of infectious viral release by
MK-8742. (left panel) Concentration-related MK-8742 suppression of virus release at 12,
24, 48 and 72 hrs was determined as for other DAAs in panel B. (center panel) Experimental
design for determining the impact of short-term DAA (MK-8742, LDV or HCV-796)
treatment on infectious virus release. DAAs were added at 2 hr intervals to H77S.3-infected
cells at concentrations equivalent to 5× EC90 in the 72 hr GLuc assay (Fig. 1). At 6 hrs,
medium was removed from all cultures and replaced with fresh medium containing the
compounds. Supernatant fluids were harvested 3 hrs later and infectious virus quantified by
FFU assay. (right panel) Infectious virus titer of supernatant fluids at time of harvest
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determined by FFU assay. The experiment was done in triplicate and is representative of
multiple experiments. DAA concentrations were: MK-8742 0.075 nM, LDV 0.86 nM, and
HCV-796 1110 nM.
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Figure 3.
Inhibition of HCV RNA synthesis by NS5A inhibitors. (A) Inhibition of viral RNA
synthesis in H77S.3-infected cells by (left) BOC or (right) LDV. RNA synthesis was
measured by incorporation of 5-ethynyl uridine into nascent HCV RNA between 2–12 hrs
after addition of the DAAs to the culture medium (see Methods). (left panel) BOC treatment
resulted in a 97% reduction of RNA synthesis at the highest concentrations tested (EC50 =
4688 nM, 95% C.I. = 3279–6742 nM). (right panel) The maximal inhibition of RNA
synthesis by LDV was 52% and was achieved at low concentrations of the drug (50%
maximal suppression at 0.056 nM, 95% C.I.=0.036–0.086 nM) and not increased at much
higher concentrations. (B) Kinetic analysis of the inhibition of RNA synthesis by MK-8742.
Genotype 1b subgenomic RNA replicon cells were studied as in panel A, with cells
harvested at intervals following addition of the compound. Results shown represent the
number of copies of newly synthesized replicon RNAs at each time point, and reveal a shut-
off of RNA synthesis at ~8 hrs in MK-8742 cells.
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Figure 4.
NS5A inhibitors block intracellular assembly of HCV. (A) Inhibition of intracellular
infectious virus (red) and cell-free virus released from infected cells (blue) following 24 hrs
treatment with LDV. Intracellular and extracellular virus were quantified in FFU assays.
Results are expressed as % inhibition and overlaid for comparison. (B) Rate-zonal
centrifugation of cell lysates derived from H77S.3-transfected cells that were either mock-
treated (0.0575% DMSO, top panel) or treated with LDV at ~3× the EC90 in the GLuc assay
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(575pM, bottom panel) for 6 or 12 hrs. Fractions collected from the top of the gradients
were tested for HCV RNA by qRT-PCR and for infectivity by FFU assay.
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Figure 5.
Antiviral activity of LDV against resistance-associated variants (RAVs). (A) Antiviral
resistance (fold-increase in EC50) and relative replication fitness of Y93H, Q30R, and L31V
mutants compared with parental H77S.3 virus (‘wt’) were determined in GLuc and FFU
reduction assays at 72 hrs (wt fitness set arbitrarily at 100). ‘n.d.’ = not determined
(precluded by low fitness). Results shown represent means ± s.d. (B) LDV-mediated
inhibition of (top panel) GLuc secretion and (lower panel) infectious virus release at 24, 48,
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and 72 hrs following addition of drug to L31V virus-infected cells. The antiviral effect
against the parental virus (‘wt’) at 72 hrs is shown for comparison.
McGivern et al. Page 19
Gastroenterology. Author manuscript; available in PMC 2015 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Antiviral activity of compound 23, a selective PI4KIIIα inhibitor30. (A) Kinetic analysis
showing (left panel) a concentration-dependent bi-phasic response to compound 23 in the
GLuc assay that measures GLuc secreted by cells replicating H77S.3/GLuc2a virus and
(right panel) compound 23 inhibition of release of infectious H77S.3 virus. Results shown
represent the mean ± s.e.m. from triplicate cell cultures. (B) Compound 23 inhibition of
H77S.3 RNA synthesis measured by incorporation of 5-EU into nascent RNA between 2–12
hrs after addition of the compound to the culture medium as in Fig 4. Results shown
represent the mean ± s.e.m. from replicate independent experiments.
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